Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Finkelstein

Radiation Oncology Syracuse, NY Medical Doctor

NPI 1700078409 CMS profile 168302

1226 E Water St, Syracuse, NY 13210

Open in the dashboard

General payments

$578,032

962 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,032,137 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Steven Finkelstein of Syracuse, NY is reported in the CMS Open Payments database as having received $578,032 across 962 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,032,137 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113,264 102
2024 General $58,064 117
2023 General $63,067 146
2022 General $82,761 150
2021 General $95,143 172
2020 General $75,802 120
2019 General $89,930 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Finkelstein
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Steven Finkelstein were reported at $113,264. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Steven Finkelstein Radiation Oncology median Middle half National median
2019 $89,930 $138 $48–$462 $163
2020 $75,802 $79 $26–$262 $114
2021 $95,143 $119 $37–$358 $132
2022 $82,761 $139 $43–$424 $149
2023 $63,067 $167 $57–$473 $160
2024 $58,064 $168 $56–$541 $164
2025 $113,264 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Progenics Pharmaceuticals, Inc. $145,544 55 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $138,876 133 payments
  3. Janssen Biotech, Inc. $71,753 130 payments
  4. Novartis Pharmaceuticals Corporation $37,978 96 payments
  5. AstraZeneca Pharmaceuticals LP $31,127 48 payments
  6. Astellas Pharma US Inc $28,388 42 payments
  7. Blue Earth Diagnostics Limited $26,293 20 payments
  8. Bioprotect Medical, Inc. $25,019 16 payments
  9. Tolmar, Inc. $15,240 2 payments
  10. Pfizer Inc. $11,200 24 payments
  11. Other $46,616 396 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $266,553 105 payments
  2. Consulting Fee $204,350 53 payments
  3. Travel and Lodging $49,184 108 payments
  4. Honoraria $31,610 9 payments
  5. Food and Beverage $21,240 679 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 5 payments
  7. Education $94 3 payments
Products named General payments · program years 2019–2025
  1. PYLARIFY $145,544 55 payments
  2. Xofigo $109,865 108 payments
  3. ERLEADA $75,405 118 payments
  4. XTANDI $36,559 50 payments
  5. Nubeqa $32,391 33 payments
  6. IMFINZI $25,301 21 payments
  7. BIOPROTECT BALLOON IMPLANT SYSTEM $25,019 16 payments
  8. PLUVICTO $17,645 22 payments
  9. ELIGARD $13,440 1 payment
  10. ORGOVYX $13,047 5 payments
  11. Other $65,718 694 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$701,455

Medicare's payments for the services billed

Medicare patients

248

Average age 75

Services billed

3,935

73 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 55%
Diabetes 33%
Ischemic heart disease 32%
Chronic kidney disease 27%
COPD 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PYLARIFY
$26,945 — —
IMFINZI
$7,567 — —
POSLUMA
$3,920 — —
Xofigo
$1,503 — —
PLUVICTO
$1,483 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

962 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record